Table 3 Proportion of self-reported treated malaria episodes in which an anti-malarial currently recommended by the Ugandan MOH was used, by trimester of pregnancy
From: Patterns of anti-malarial drug treatment among pregnant women in Uganda
1st Trimester | TOTAL (n = 126 episodes*) | (95% CI)+ |
|---|---|---|
Currently recommended | Â | Â |
Quinine monotherapy; n (%) | 7 (5.6) | (2.5, 10.7) |
Not currently recommended | 119 (94.4) | (89.3, 97.5) |
SP monotherapy; n (%) | 29 (23.0) | Â |
Chloroquine monotherapy; n (%) | 18 (14.3) | Â |
SP+Chloroquine; n (%) | 6 (4.8) | Â |
Any AL; n (%) | 53 (42.1) | Â |
AL alone; n | 26 | Â |
AL +1 other anti-malarial1; n | 21 | Â |
AL + 2 or more other anti-malarials2; n | 6 | Â |
Other; n (%) | 13 (10.3) | Â |
2 nd or 3 rd Trimester | TOTAL (n = 478 episodes*) | Â |
Currently recommended | 144 (30.1) | (26.1, 34.3) |
AL alone; n (%) | 113 (23.6) | Â |
Quinine monotherapy; n (%) | 28 (5.9) | Â |
AL + quinine** | 3 (0.6) | Â |
Not currently recommended | 334 (69.9) | (65.6, 73.9) |
SP monotherapy; n (%) | 132 (27.6) | Â |
AL +1 other anti-malarial3; n | 78 (16.3) | Â |
Chloroquine monotherapy; n (%) | 31 (6.5) | Â |
SP+Chloroquine; n (%) | 23 (4.8) | Â |
AL + 2 or more other anti-malarials4; n | 13 (2.7) | Â |
SP+Quinine | 5 (1.1) | Â |
Other; n (%) | 52 (10.9) | Â |
Any use of a currently recommended anti-malarial***; n (%) | 240 (50.2) | (45.7, 54.7) |
Any use of AL; n (%) | 207 (43.3) | Â |
Any use of quinine; n (%) | 33 (6.9) | Â |